CO2019008657A2 - Composición intranasal que comprende betahistina - Google Patents

Composición intranasal que comprende betahistina

Info

Publication number
CO2019008657A2
CO2019008657A2 CONC2019/0008657A CO2019008657A CO2019008657A2 CO 2019008657 A2 CO2019008657 A2 CO 2019008657A2 CO 2019008657 A CO2019008657 A CO 2019008657A CO 2019008657 A2 CO2019008657 A2 CO 2019008657A2
Authority
CO
Colombia
Prior art keywords
betahistine
intranasal composition
intranasal
neurological
pharmaceutically acceptable
Prior art date
Application number
CONC2019/0008657A
Other languages
English (en)
Inventor
Christopher John Wraight
Thomas Meyer
Original Assignee
Otolanum Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otolanum Ag filed Critical Otolanum Ag
Publication of CO2019008657A2 publication Critical patent/CO2019008657A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Abstract

La presente descripción se refiere a una composición farmacéutica que comprende, como sustancia activa, betahistina o una sal farmacéuticamente aceptable de esta, para su uso en el tratamiento de trastornos neurológicos u otológicos en un sujeto humano mediante aplicación intranasal
CONC2019/0008657A 2017-02-02 2019-08-09 Composición intranasal que comprende betahistina CO2019008657A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762453931P 2017-02-02 2017-02-02
PCT/EP2018/052695 WO2018141922A1 (en) 2017-02-02 2018-02-02 Intranasal composition comprising betahistine

Publications (1)

Publication Number Publication Date
CO2019008657A2 true CO2019008657A2 (es) 2020-01-17

Family

ID=61187302

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0008657A CO2019008657A2 (es) 2017-02-02 2019-08-09 Composición intranasal que comprende betahistina

Country Status (34)

Country Link
US (2) US10456386B2 (es)
EP (2) EP3698791B1 (es)
JP (3) JP2020506930A (es)
KR (1) KR102653545B1 (es)
CN (1) CN110418643A (es)
AR (1) AR111699A1 (es)
AU (1) AU2018216970B2 (es)
BR (1) BR112019015687A2 (es)
CA (1) CA3051725A1 (es)
CL (1) CL2019002145A1 (es)
CO (1) CO2019008657A2 (es)
DK (2) DK3698791T3 (es)
EA (1) EA201991817A1 (es)
ES (1) ES2807798T3 (es)
FI (1) FI3698791T3 (es)
HR (2) HRP20231706T1 (es)
HU (1) HUE050829T2 (es)
IL (1) IL268353B2 (es)
LT (2) LT3474850T (es)
MA (1) MA46778B1 (es)
MX (1) MX2019008961A (es)
MY (1) MY196333A (es)
NZ (1) NZ755931A (es)
PH (1) PH12019501785A1 (es)
PL (2) PL3698791T3 (es)
PT (2) PT3474850T (es)
RS (2) RS60554B1 (es)
SA (1) SA519402324B1 (es)
SG (1) SG11201906980YA (es)
SI (1) SI3474850T1 (es)
TN (1) TN2019000220A1 (es)
TW (1) TWI760429B (es)
WO (1) WO2018141922A1 (es)
ZA (1) ZA201904955B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170532A1 (en) * 2017-03-22 2018-09-27 Franz, Lilian Ann Treatment method
CA3179806A1 (en) * 2020-04-14 2021-10-21 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Nasal spray formulation with moisturizing benefits

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2397840B1 (es) 1977-07-22 1981-03-20 Cherqui Jean
IT1229237B (it) * 1989-05-08 1991-07-26 Prodotti Formenti Sali di (2-(piridil)etil) metilammina
JPH03287535A (ja) * 1990-03-31 1991-12-18 Bairon Boeki Kk プラノプロフェン水溶液
JP3203056B2 (ja) * 1992-08-13 2001-08-27 株式会社ティ・ティ・エス技術研究所 メシル酸ベタヒスチンの経皮吸収製剤用組成物および経皮吸収製剤
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
JPH10139667A (ja) * 1996-11-15 1998-05-26 Yoshitomi Pharmaceut Ind Ltd 水性液剤
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
JP3555598B2 (ja) 2001-06-27 2004-08-18 株式会社村田製作所 積層型インダクタ
JP2004196676A (ja) * 2002-12-16 2004-07-15 Rohto Pharmaceut Co Ltd 点鼻剤
JP4733333B2 (ja) * 2002-12-26 2011-07-27 ライオン株式会社 点鼻剤又は洗鼻剤
SI1530965T1 (sl) 2003-11-11 2006-06-30 Mattern Udo Formulacija za nasalno aplikacijo z nadzorovanim sproscanjem spolnih hormonov
AU2006202950A1 (en) * 2004-04-22 2006-10-19 Mor Research Applications Ltd. Methods and Compositions for Weight Management
CA2553309A1 (en) * 2004-04-22 2005-11-03 Mor Research Applications Ltd. Method of food intake management
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
EP2457580A1 (en) 2004-08-25 2012-05-30 The UAB Research Foundation Absorption enhancers for drug administration
JP2009504767A (ja) * 2005-08-17 2009-02-05 フレミング・アンド・カンパニー・ファーマシューティカルズ ビタミンｂ１２鼻用スプレーおよび使用方法
WO2007076140A2 (en) 2005-12-23 2007-07-05 University Of Cincinnati Treatment methods employing histamine h3 receptor antagonists, including betahistine
US8242148B2 (en) * 2005-12-23 2012-08-14 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
RU2010129833A (ru) * 2007-12-21 2012-01-27 Шеринг-Плау Хельскер Продактс, Инк. (Us) Повышение светоустойчивости оксиметазолина
MX2010011545A (es) * 2008-04-21 2011-04-11 Otonomy Inc Formulaciones para tratar enfermedades y afecciones del oido.
CN102046170B (zh) * 2008-05-27 2012-11-28 墨尔本大学 治疗患有咽鼓管功能障碍的哺乳动物的方法
BRPI0919811B1 (pt) * 2008-10-08 2022-04-19 Xgene Pharmaceutical Inc Conjugados de gaba e métodos de uso dos mesmos
EP3200828B1 (en) * 2014-10-03 2020-08-12 Lachesis Biosciences Limited Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders

Also Published As

Publication number Publication date
SG11201906980YA (en) 2019-08-27
MA46778A1 (fr) 2021-04-30
WO2018141922A1 (en) 2018-08-09
US10456386B2 (en) 2019-10-29
MY196333A (en) 2023-03-24
TN2019000220A1 (en) 2021-01-07
BR112019015687A2 (pt) 2020-04-28
PL3698791T3 (pl) 2024-04-08
IL268353A (en) 2019-09-26
LT3474850T (lt) 2020-08-10
HRP20201137T1 (hr) 2021-01-22
HRP20231706T1 (hr) 2024-03-15
AU2018216970A1 (en) 2019-08-22
EP3698791A1 (en) 2020-08-26
DK3474850T3 (da) 2020-08-03
MA46778B1 (fr) 2022-08-31
NZ755931A (en) 2022-07-29
ZA201904955B (en) 2021-05-26
LT3698791T (lt) 2024-02-12
PT3474850T (pt) 2020-07-27
US20200022963A1 (en) 2020-01-23
CN110418643A (zh) 2019-11-05
AR111699A1 (es) 2019-08-14
EA201991817A1 (ru) 2020-01-27
SI3474850T1 (sl) 2020-09-30
EP3474850B1 (en) 2020-04-22
JP2024019731A (ja) 2024-02-09
TW201831179A (zh) 2018-09-01
KR102653545B1 (ko) 2024-04-04
RS65099B1 (sr) 2024-02-29
IL268353B1 (en) 2023-06-01
US20180214432A1 (en) 2018-08-02
EP3474850A1 (en) 2019-05-01
RS60554B1 (sr) 2020-08-31
JP2022051872A (ja) 2022-04-01
CA3051725A1 (en) 2018-08-09
PH12019501785A1 (en) 2020-07-06
FI3698791T3 (fi) 2024-01-11
KR20190116341A (ko) 2019-10-14
DK3698791T3 (da) 2024-01-15
EP3698791B1 (en) 2023-10-25
JP2020506930A (ja) 2020-03-05
ES2807798T3 (es) 2021-02-24
TWI760429B (zh) 2022-04-11
PL3474850T3 (pl) 2020-09-21
SA519402324B1 (ar) 2023-03-16
PT3698791T (pt) 2024-01-12
MX2019008961A (es) 2019-10-15
CL2019002145A1 (es) 2019-11-04
HUE050829T2 (hu) 2021-01-28
AU2018216970B2 (en) 2023-12-21
IL268353B2 (en) 2023-10-01

Similar Documents

Publication Publication Date Title
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2016001895A1 (es) Compuestos
CO2021007993A2 (es) Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
GT201600269A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
PE20151005A1 (es) Composicion farmaceutica recubierta que contiene regorafenib
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
CL2015002546A1 (es) Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos
CR20180493A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
PE20160052A1 (es) Composicion farmaceutica de clorhidrato de s-cetamina
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
UY37379A (es) Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades
PE20171243A1 (es) Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
GT201700016A (es) [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
CL2015001187A1 (es) Compuestos derivados de azaquinolin-carboxamida, como inhibidores de p70s6k; su metodo de manufactura; composicion farmaceutica que los comprende; y su uso para el tratamiento profilactico o terapeutico de trastornos hiperproliferativos, cancer, retinopatia diabetica, dolor, eczema y degeneracion macular relacionada con la edad, entre otras enfermedades.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CO2019008657A2 (es) Composición intranasal que comprende betahistina
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso